致癌途径对逃避抗肿瘤免疫反应的影响。
Impact of oncogenic pathways on evasion of antitumour immune responses.
机构信息
The Koch Institute for Integrative Cancer Research at MIT and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Department of Pathology, University of Chicago.
出版信息
Nat Rev Cancer. 2018 Mar;18(3):139-147. doi: 10.1038/nrc.2017.117. Epub 2018 Jan 12.
Abstract
Immunotherapeutic interventions are showing effectiveness across a wide range of cancer types, but only a subset of patients shows clinical response to therapy. Responsiveness to checkpoint blockade immunotherapy is favoured by the presence of a local, CD8 T cell-based immune response within the tumour microenvironment. As molecular analyses of tumours containing or lacking a productive CD8 T cell infiltrate are being pursued, increasing evidence is indicating that activation of oncogenic pathways in tumour cells can impair induction or execution of a local antitumour immune response. This Review summarizes our current knowledge of the influence of oncogenic effects on evasion of antitumour immunity.
摘要
免疫治疗干预在多种癌症类型中显示出疗效，但只有一部分患者对治疗有临床反应。在肿瘤微环境中存在局部 CD8 T 细胞为基础的免疫反应有利于检查点阻断免疫治疗的反应性。随着对含有或缺乏有效 CD8 T 细胞浸润的肿瘤进行分子分析的进行，越来越多的证据表明，肿瘤细胞中致癌途径的激活会损害局部抗肿瘤免疫反应的诱导或执行。这篇综述总结了我们目前对致癌效应影响抗肿瘤免疫逃逸的认识。
相似文献
1
Impact of oncogenic pathways on evasion of antitumour immune responses.致癌途径对逃避抗肿瘤免疫反应的影响。
Nat Rev Cancer. 2018 Mar;18(3):139-147. doi: 10.1038/nrc.2017.117. Epub 2018 Jan 12.
2
PTEN loss correlates with T cell exclusion across human cancers.PTEN 缺失与人类癌症中的 T 细胞排斥相关。
BMC Cancer. 2021 Apr 19;21(1):429. doi: 10.1186/s12885-021-08114-x.
3
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.在T细胞炎症性和非T细胞炎症性肿瘤微环境背景下的肿瘤逃逸机制。
Int Immunol. 2016 Aug;28(8):383-91. doi: 10.1093/intimm/dxw014. Epub 2016 Mar 17.
4
CD8 cytotoxic T lymphocytes in cancer immunotherapy: A review.癌症免疫治疗中的 CD8 细胞毒性 T 淋巴细胞：综述。
J Cell Physiol. 2019 Jun;234(6):8509-8521. doi: 10.1002/jcp.27782. Epub 2018 Nov 22.
5
WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.WNT/β-连环蛋白信号通路调节肿瘤微环境中的 T 细胞炎症。
Front Immunol. 2019 Sep 26;10:2293. doi: 10.3389/fimmu.2019.02293. eCollection 2019.
6
Emerging role of PTEN loss in evasion of the immune response to tumours.PTEN 缺失在肿瘤免疫逃避中的新作用。
Br J Cancer. 2020 Jun;122(12):1732-1743. doi: 10.1038/s41416-020-0834-6. Epub 2020 Apr 24.
7
Signaling defects in anti-tumor T cells.抗肿瘤T细胞中的信号缺陷。
Immunol Rev. 2008 Apr;222:192-205. doi: 10.1111/j.1600-065X.2008.00606.x.
8
Intrinsic β-catenin signaling suppresses CD8 T-cell infiltration in colorectal cancer.内在 β-连环蛋白信号抑制结直肠癌中的 CD8 T 细胞浸润。
Biomed Pharmacother. 2019 Jul;115:108921. doi: 10.1016/j.biopha.2019.108921. Epub 2019 May 8.
9
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8 T cells.腺苷介导外周和肿瘤浸润的 CD8 T 细胞的功能和代谢抑制。
J Immunother Cancer. 2019 Oct 10;7(1):257. doi: 10.1186/s40425-019-0719-5.
10
Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.鳞状细胞癌通过诱导共表达PD-1和LAG-3抑制性受体的CD8+ T细胞的慢性激活和耗竭来逃避免疫监视。
Oncotarget. 2016 Dec 6;7(49):81341-81356. doi: 10.18632/oncotarget.13228.
引用本文的文献
1
Mutations in MLL3 promote breast cancer progression via HIF1α-dependent intratumoral recruitment and differentiation of regulatory T cells.MLL3中的突变通过HIF1α依赖的肿瘤内调节性T细胞募集和分化促进乳腺癌进展。
Immunity. 2025 Aug 12;58(8):2035-2053.e9. doi: 10.1016/j.immuni.2025.07.008. Epub 2025 Jul 31.
2
Targeting p-FGFR1 Enhances CD8+ T Cells Infiltration and Overcomes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma by Regulating the CXCL8-CXCR2 Axis.靶向磷酸化成纤维细胞生长因子受体1通过调节CXCL8-CXCR2轴增强CD8 + T细胞浸润并克服食管鳞状细胞癌的免疫治疗耐药性。
Biomedicines. 2025 Jul 8;13(7):1667. doi: 10.3390/biomedicines13071667.
3
Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer.帕博利珠单抗与放疗联合可在免疫冷型非小细胞肺癌中诱导全身抗肿瘤免疫反应。
Nat Cancer. 2025 Jul 22. doi: 10.1038/s43018-025-01018-w.
4
The TP53 tumor suppressor gene: From molecular biology to clinical investigations.TP53肿瘤抑制基因：从分子生物学到临床研究
J Intern Med. 2025 Aug;298(2):78-96. doi: 10.1111/joim.20106. Epub 2025 Jun 16.
5
Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression.肿瘤浸润淋巴细胞和三级淋巴结构在胃癌进展中的作用与功能。
Front Immunol. 2025 May 29;16:1595070. doi: 10.3389/fimmu.2025.1595070. eCollection 2025.
6
Tumor-associated macrophages (TAMs): Constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC).肿瘤相关巨噬细胞（TAMs）：为胰腺导管腺癌（PDAC）构建免疫抑制微环境桥梁
Cancer Pathog Ther. 2024 Jul 23;3(3):183-196. doi: 10.1016/j.cpt.2024.07.004. eCollection 2025 May.
7
Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers.论背景、质量与复杂性：梳理免疫治疗癌症中的肿瘤突变负荷
Clin Cancer Res. 2025 Jul 15;31(14):2850-2863. doi: 10.1158/1078-0432.CCR-23-0824.
8
MYC controls STING levels to downregulate inflammatory signaling in breast cancer cells upon DNA damage.MYC通过控制STING水平来下调乳腺癌细胞在DNA损伤时的炎症信号。
J Biol Chem. 2025 Apr 29;301(6):108560. doi: 10.1016/j.jbc.2025.108560.
9
The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates.类器官在研究胃癌微环境中的免疫逃逸及筛选新型候选药物中的应用。
Mol Cancer. 2025 Apr 26;24(1):125. doi: 10.1186/s12943-025-02328-4.
10
Smad4 loss identifies aggressive subtype with immunotherapy and anti-HER-2 treatment resistance in gastric cancer.Smad4缺失可识别出在胃癌中对免疫疗法和抗HER-2治疗具有抗性的侵袭性亚型。
Br J Cancer. 2025 Apr 25. doi: 10.1038/s41416-025-03002-8.
本文引用的文献
1
The spectrum of T cell metabolism in health and disease.T 细胞代谢在健康和疾病中的图谱。
Nat Rev Immunol. 2018 Jan;18(1):19-34. doi: 10.1038/nri.2017.99. Epub 2017 Sep 25.
2
Genomic Activation of Reveals a Candidate Therapeutic Axis in Bladder Cancer.[基因名称]的基因组激活揭示了膀胱癌中的一个候选治疗轴。 （你原文中“of ”后面缺少具体内容，请补充完整以便准确翻译）
Cancer Res. 2017 Dec 15;77(24):6987-6998. doi: 10.1158/0008-5472.CAN-17-1701. Epub 2017 Sep 18.
3
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.溶瘤病毒疗法可促进肿瘤内T细胞浸润并改善抗PD-1免疫疗法。
Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.
4
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.一名卵巢癌患者中不同生长速度转移灶间的异质性肿瘤免疫微环境
Cell. 2017 Aug 24;170(5):927-938.e20. doi: 10.1016/j.cell.2017.07.025.
5
Targeting neoantigens to augment antitumour immunity.靶向新抗原以增强抗肿瘤免疫力。
Nat Rev Cancer. 2017 Aug 24;17(9):569. doi: 10.1038/nrc.2017.74.
6
Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling.树突状细胞而非巨噬细胞通过信号调节蛋白α信号传导感知肿瘤线粒体DNA进行交叉呈递。
Immunity. 2017 Aug 15;47(2):363-373.e5. doi: 10.1016/j.immuni.2017.07.016. Epub 2017 Aug 8.
7
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.干扰素-γ相关的mRNA谱可预测对PD-1阻断的临床反应。
J Clin Invest. 2017 Aug 1;127(8):2930-2940. doi: 10.1172/JCI91190. Epub 2017 Jun 26.
8
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
9
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.肿瘤驻留的Batf3树突状细胞是效应T细胞转运和过继性T细胞治疗所必需的。
Cancer Cell. 2017 May 8;31(5):711-723.e4. doi: 10.1016/j.ccell.2017.04.003.
10
Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.基线β-连环蛋白、程序性死亡配体1表达和肿瘤浸润淋巴细胞可预测BRAF抑制剂治疗的黑色素瘤患者的反应及不良预后。
Eur J Cancer. 2017 Jun;78:70-81. doi: 10.1016/j.ejca.2017.03.012. Epub 2017 Apr 14.
Zotero 插件